← Back to Search

P2Y12 receptor antagonist

Ticagrelor for Coronary Artery Disease

Phase 2 & 3

Waitlist Available

Research Sponsored by First Affiliated Hospital of Harbin Medical University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 month

Awards & highlights

Study Summary

This trial is to study the effects of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease.

Who is the study for?

This trial is for diabetic patients with stable coronary artery disease, including various types of angina or those asymptomatic on therapy. It's not for individuals who recently had acute coronary syndromes, plan to use certain heart medications during the study, have low platelet counts or kidney function, severe heart failure, a history of bleeding issues, or allergies to Ticagrelor or clopidogrel.Check my eligibility

What is being tested?

The trial tests different doses of Ticagrelor against a standard dose of clopidogrel in preventing blood clots and improving endothelial function (which helps regulate blood pressure) in diabetic patients with stable heart disease. The goal is to see if lower doses of Ticagrelor are more beneficial than the usual treatment with clopidogrel.See study design

What are the potential side effects?

Possible side effects include increased risk of bleeding due to the anti-clotting nature of both drugs. Patients may also experience shortness of breath or allergic reactions specific to each medication.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Inhibition of platelet aggregation

Secondary outcome measures

Endothelial Function

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Ticagrelor 90 mgExperimental Treatment1 Intervention

Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.

Group II: Ticagrelor 45 mgExperimental Treatment1 Intervention

Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.

Group III: Ticagrelor 22.5 mgExperimental Treatment1 Intervention

Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.

Group IV: ClopidogrelActive Control1 Intervention

Clopidogrel (75mg, once daily, oral) treatment for 1 month.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ticagrelor

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

First Affiliated Hospital of Harbin Medical UniversityLead Sponsor

136 Previous Clinical Trials

1,370,327 Total Patients Enrolled

9 Trials studying Coronary Artery Disease

7,296 Patients Enrolled for Coronary Artery Disease

Media Library

Clopidogrel (P2Y12 receptor antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT02889549 — Phase 2 & 3

Coronary Artery Disease Research Study Groups: Ticagrelor 22.5 mg, Ticagrelor 45 mg, Ticagrelor 90 mg, Clopidogrel

Coronary Artery Disease Clinical Trial 2023: Clopidogrel Highlights & Side Effects. Trial Name: NCT02889549 — Phase 2 & 3

Clopidogrel (P2Y12 receptor antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02889549 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research project prohibit senior citizens from participating?

"This study is enrolling individuals that are between 18 and 75 years old."

Answered by AI

What conditions does ticagrelor help alleviate?

"Ticagrelor is often used to manage myocardial infarction, however it can also be taken as a preventative measure for those with stent placement, cerebrovascular accident, or coronary artery disease."

Answered by AI

Are there any specific inclusionary criteria for this research?

"Sixty patients experiencing coronary artery disease, aged 18 to 75, who meet the following requirements may participate in this study: having stable angina, low-risk unstable angina, variant angina, or being asymptomatic with appropriate therapy which includes percutaneous coronary intervention."

Answered by AI

Can you please share what prior research has been conducted on ticagrelor?

"As of now, there are 82 different medical studies that remain active and are investigating ticagrelor. Out of these, 21 trials have reached Phase 3. Although a majority of the research is based in Beijing, China, there are 873 total locations where ticagrelor clinical trials are taking place."

Answered by AI